Serinus Biosciences

Executive Summary

Serinus Biosciences is a San Diego-based biotechnology company founded in 2020, operating at the intersection of oncology and immunology. The company is developing novel immunotherapies and targeted therapies for cancer and autoimmune diseases. As a private, early-stage entity, Serinus has not yet disclosed specific pipeline candidates or clinical trial phases. However, its focus on immuno-oncology and autoimmune indications positions it within a high-demand therapeutic area. The company benefits from its location in San Diego's vibrant biotech ecosystem, providing access to talent and potential partnerships. While detailed financials and valuation are not publicly available, Serinus is likely advancing preclinical programs toward IND-enabling studies. The company's success will hinge on its ability to generate compelling preclinical data and secure funding or partnerships to progress into clinical trials.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Immuno-Oncology Candidate60% success
• Q2 2026Preclinical Data Presentation at Major Conference (e.g., SITC or AACR)70% success
• TBDSeries A Funding Announcement50% success